Glancy Binkow & Goldberg LLP is Investigating Durata Therapeutics, Inc. Board of Directors

Glancy Binkow & Goldberg LLP is investigating potential claims against the Board of Directors of Durata Therapeutics, Inc. (“Durata” or the “Company”) (NASDAQ:DRTX) related to the proposed acquisition of the Company by Actavis PLC. The transaction is valued at approximately $675 million, or $23.00 per share.

This investigation concerns whether the Board of Directors of Durata breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the proposed transaction, and whether the Company has disclosed all material information to shareholders about the transaction. Further, at least one analyst has set a target price for the Company’s stock at $26.00 per share.

If you are a shareholder of Durata, if you have information or would like to learn more about our investigation, or if you wish to discuss your rights or interests with respect to these matters, please contact Louis Boyarsky, Esquire, Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067, by telephone at (310) 201-9150 or Toll Free at (888) 773-9224 or by email to shareholders@glancylaw.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Binkow & Goldberg LLPLouis Boyarsky, Esquire(310) 201-9150Toll Free: (888) 773-9224shareholders@glancylaw.com

(MM) (NASDAQ:DRTX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024